Insights

Webinar - Audit with confidence: Preparing and executing effective GMP audits

Specialty distribution: An integrated approach to pharmaceutical distribution

Key features of an effective medical information service

Synopsis of Draft Guidance on Health Canada’s T&Cs

Foreign action notification to Health Canada

The value of RWE collected through PSPs

Quality, regulatory, safety: Meeting a collective compliance need

Navigating the new era of Canadian medical device regulations: What MDEL holders need to know

Case study: Enabling shared access - Digitized solutions to increase visibility and facilitate streamlined communication between a patient support program (PSP) and manufacturer

Transforming Patient Support Program (PSP) enrolment to enhance user experiences and optimize workflows

Webinar: Health Canada Clinical Trials Regulatory Modernization

Integrated quality, regulatory, and safety services 

Collaborative approach to oncology care

Understanding PRCI and Its Requirements

Key insights from RAPS Convergence 2025

Navigating Canadian environmental regulations: A case study on NSNR compliance

The value of real-world evidence in Canadian drug commercialization

What you need to know about renewing your Drug Establishment Licence (DEL)

Innomar’s commitment to drug safety standards

Case Study: Medical device licensing prior to authorization of accompanying drug

Understanding XML Product Monographs

Case Study: Optimizing Procedures - Achieving Excellence in Medical Device Management

Pharmacovigilance: Canadian requirements

Manufacturers

QA consultants: Easing entry into the Canadian market

Moving the Needle on Innovation: A view into 2025 and integrated patient services

Leveraging digital solutions to accelerate access to therapy

Manufacturers

Market access: Navigating the Canadian reimbursement landscape

Manufacturers

Canadian drug listing: Optimizing time to reimbursement

Manufacturers

Market access in Canada: Current trends

Manufacturers

Drug advertisement in Canada: What you need to know

Manufacturers

Regulatory compliance: Navigating the Canadian landscape for specialty products

Manufacturers

Streamlining AE Management with Automated Solutions

Manufacturers

Innovative logistics solutions for specialty medications

Manufacturers

Patient support programs: A significant source of real-world data

Manufacturers

Real world evidence: The importance for rare disease therapies

Manufacturers

Innomar Strategies: Comprehensive 3PL and QA services

Manufacturers

QA and 3PL licences: Helping you stay compliant

Webinar on-demand - A Panel Discussion on Navigating Medical Devices in Canada

Manufacturers

Achieving quality assurance excellence for a client

Manufacturers

Drug development checklist: what to look for in a commercialization partner

Manufacturers

Pre-launch checklist: what to look for in a commercialization partner

Manufacturers

Post launch checklist: what to look for in a commercialization partner

Manufacturers

InnomarLive 2023: Part One

Manufacturers

InnomarLive 2023: Part Two

Manufacturers

InnomarLive 2023: Part Three

Manufacturers

Reuters Cell & Gene Therapy USA 2022 – RWE for Market Access

Manufacturers

Regulatory Services: Management and Control of Certified Product Information Document

Manufacturers

COVID-19 Vaccine Distribution

Unlocking Access Building a National Strategy to Support Canadians with Rare Diseases

Manufacturers

Commercializing cell and gene therapies in Canada

Manufacturers

The Drug Reimbursement Environment in Canada: An Overview

Manufacturers

Digital innovation in patient support

Manufacturers

Webinar: Impact of COVID-19 on Patient Support Programs in Canada

Manufacturers

Innomar Strategies: 20 years of innovative market access solutions

Manufacturers

Case Study: Launching a new molecule for a rare disease

Manufacturers

Case Study: A proven approach for an emerging specialty pharma company

Manufacturers

Case Study: A flexible solution for launching a new molecule in oncology

Manufacturers

The value of Real-World Evidence in Canadian drug commercialization: Part 2

Manufacturers

Webinar: Utilizing Real World Evidence Across the Product Life Cycle

Manufacturers

Market Access: Reimbursement

Manufacturers

Time-to-treatment initiation (TTI) in community infusion clinics - decreasing wait times for Canadian oncology patients

Manufacturers

Commercializing in Canada: Quality Assurance and GMP Services

Manufacturers

Commercializing in Canada: Regulatory Publishing and Submissions

Manufacturers

Webinar: Health Canada’s Regulatory and Quality approach to addressing COVID-19 challenges

Manufacturers

Insight Series: The Value of Real-World Evidence in Canadian Drug Commercialization – Part 1

InnomarLive Summary: Healthcare Innovation

Manufacturers

Insight Series: Value of Patient Support Programs for Specialty Medications in Canada

Insight Series: Biosimilars in Canada

Drug Reimbursement in Canada

Improved Health Outcomes in Patients Receiving Health Case Management

Understanding the Journey of a Person with a Rare Disease

Specialty pharmacies enhance patient outcomes [Pharmacy Practice Plus]

Case Study: Patient-centric Care in Rare Disease

Future of Patient Support Programs in Canada

Case Study: Leveraging Physician Relationships to Co-create Patient Support

Case Study: Discovering New Opportunities for Growth in a Niche Market

Case Study: Optimizing a Patient Support Program to Improve Therapy Adherence

Support Programs Designed to Assist Patients and Their Families

Big Wins in Record Time for Gaining Market Access with Phase II Data

Nurse-led Health Case Management